In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder Leadership Realignment Reflects Global Strategy

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder is realigning its business structure under four group presidents to reflect a more global structure and expand its reach within the 120 countries and territories to which it markets, the firm announced May 17.

You may also be interested in...



Estee Lauder, Clinique Appoint North American Presidents

Estee Lauder has appointed Janet Cook North American president for the Estee Lauder brand, and Eunice Valdivia North American president for Clinique as part of an ongoing restructuring at the firm. The newly created positions, effective Jan. 1, reflect an initiative to strengthen sales in the region, the company said

Estee Lauder, Clinique Appoint North American Presidents

Estee Lauder has appointed Janet Cook North American president for the Estee Lauder brand, and Eunice Valdivia North American president for Clinique as part of an ongoing restructuring at the firm. The newly created positions, effective Jan. 1, reflect an initiative to strengthen sales in the region, the company said

Estee Lauder Places Bet On Spade With Premier Beauty Launch

Kate Spade's premier fragrance and bath and body care offerings slated to hit counters in May will be backed by 10 mil. samples including scented postcards announcing the launch of Kate Spade Beauty, Estee Lauder VP-Marketing Worldwide Deborah Clark said

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009241

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel